Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|September 14, 2016

Merck KGaA Joins the DiViNe Project

The project aims to address challenges facing the development, manufacture, and delivery of vaccines.

On Sept. 14, 2016, Merck KGaA Darmstadt, Germany announced that the company has joined the DiViNe Project, a European consortium of six companies to address challenges facing the development, manufacture, and delivery of vaccines. The objective of the project is to create an integrated cost effective purification program tailored for vaccines that achieve higher yields while preserving product integrity.

Merck KGaA, Darmstadt, Germany will focus on simplifying the process of vaccine purification that typically relies on affinity chromatography. Merck KGaA will provide chromatographic materials and coupling technologies for the project, the company said in a press announcement. The project’s purification platform will be tested first with heterogeneous vaccines including glycoconjugates, protein antigens, and viruses. After the platform is validated, the consortium plans to implement the platform in downstream processes for other biologics.

Other members of the consortium include Affilogic (France), Aquaporin (Denmark), GenIbet Biopharmaceuticals (Portugal), and GlaxoSmithKline (Italy). The project will be coordinated by iBET (Portugal) and has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement N° 635770.

Source: Merck KGaA

 


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.